Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 10/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | ROS1 | P08922 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12796051 | 0.94 | SYK (0.46) | SYKTNK2CHEK1JAK2ABL1 | |
| SCHEMBL1158761 | 0.94 | SYK (0.46) | SYKTNK2CHEK1JAK2ABL1 | |
| SCHEMBL1158888 | 0.94 | SYK (0.46) | SYKTNK2CHEK1JAK2ABL1 | |
| SCHEMBL12797891 | 0.89 | SYK (0.43) | SYKTNK2CHEK1JAK2ABL1 | |
| SCHEMBL1158318 | 0.82 | SYK (0.47) | SYKTNK2CHEK1JAK2ABL1 | |
| SCHEMBL1158434 | 0.82 | SYK (0.47) | SYKTNK2 | |
| SCHEMBL12796042 | 0.81 | SYK (0.60) | SYKCHEK1ALK | |
| SCHEMBL12795846 | 0.79 | SYK (0.68) | SYK | |
| SCHEMBL12797782 | 0.79 | SYK (0.68) | SYK | |
| SCHEMBL12796045 | 0.77 | SYK (0.42) | SYKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8704022-B2 | Process for producing high purity exo-alkenylnorbornene | PROMERUS, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | SYK 1/4885TNK2 120/4885HCAR3 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.